Valopicitabine

Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results

...V), respectively, and the amortization of the up-front fees received by Idenix in connection with Novartis' license of telbivudine, valtorcitabine and valopicitabine and product sales of Tyzeka/Sebivo. Idenix reported a net loss of $30.5 million, or a loss of $0.54 per basic and diluted share for the third quarter ...

Valopicitabine in Medical Technology

Idenix Reports Results from Two Phase IIb Studies of the Combination of Valopicitabine and Pegylated Interferon in Hepatitis C Genotype-1 Patients at the 42nd Annual Meeting of the European Association for the Study of the Liver

Additional Preclinical Data Presented on Valopicitabine Combined with an Investigational Protease Inhibitor BARCELONA, Spain, April 12, 2007 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. today announced results from two phase IIb studies of the novel combination of valopicitabine (NM283) ...

Idenix Announces Data Presentations at the 2007 Digestive Disease Week Meeting

...ster session beginning on Monday, May 21, 2007 at 8:00 a.m. EDT. About valopicitabine (NM283) valopicitabine is an investigational HCV RNA polymerase inhibitor being evaluated in ongoi...

Valopicitabine Combined with Standard of Care Cleared Hepatitis C Virus in 72% of Patients Who Completed 12 Weeks of Treatment in a Phase II Trial

... ~ valopicitabine achieved both primary and secondary endpoints of s...s. Patients in arm A (n=39) received 200 mg/day of valopicitabine and pegylated interferon alpha 2a; patients in arm...day lead-in period, where patients received either valopicitabine or placebo alone; the additional components of eac...

Valopicitabine in Biological News

Novel therapy combinations gain ground in treating hepatitis

... lead to more significant breakthroughs and relief for these patients." valopicitabine (NM283), Alone or with Peg-Interferon, Compared to Peg Interferon/Ribavirin...nts in patients who have not experienced remission with standard therapies: valopicitabine alone (800 mg/d), one of three combination arms with the drug at 400 mg/d, ...